Residents of long-term care facilities (LTCFs), particularly those in skilled nursing facilities (SNFs), have experienced disproportionately high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1,2). However, this group was not included in COVID-19 vaccine clinical trials, and limited postauthorization vaccine effectiveness (VE) data are available for this critical population (3). It is not known how well COVID-19 vaccines protect SNF residents, who typically are more medically frail, are older, and have more underlying medical conditions than the general population (1). In addition, immunogenicity of the Pfizer-BioNTech vaccine was found to be lower in adults aged 65-85 years than in younger adults (4). Through the CDC Pharmacy Partnership for Long-Term Care Program, SNF residents and staff members in Connecticut began receiving the Pfizer-BioNTech COVID-19 vaccine on December 18, 2020 (5). Administration of the vaccine was conducted during several on-site pharmacy clinics. In late January 2021, the Connecticut Department of Public Health (CT DPH) identified two SNFs experiencing COVID-19 outbreaks among residents and staff members that occurred after each facility's first vaccination clinic. CT DPH, in partnership with CDC, performed electronic chart review in these facilities to obtain information on resident vaccination status and infection with SARS-CoV-2, the virus that causes COVID-19. Partial vaccination, defined as the period from >14 days after the first dose through 7 days after the second dose, had an estimated effectiveness of 63% (95% confidence interval [CI] = 33%-79%) against SARS-CoV-2 infection (regardless of symptoms) among residents within these SNFs. This is similar to estimated effectiveness for a single dose of the Pfizer-BioNTech COVID-19 vaccine in adults across a range of age groups in noncongregate settings (6) and suggests that to optimize vaccine impact among this population, high coverage with the complete 2-dose series should be recommended for SNF residents and staff members.

中文翻译：

---

辉瑞-BioNTech COVID-19疫苗在两个发生COVID-19疫情的熟练护理机构中的患者的有效性-康涅狄格州，2020年12月至2021年2月。

长期护理机构（LTCF）的居民，尤其是熟练护理机构（SNFs）的居民，其COVID-19相关的发病率和死亡率高得不成比例，因此优先进行早期COVID-19疫苗接种（1,2）。但是，该组未包括在COVID-19疫苗临床试验中，并且该关键人群的授权后疫苗有效性（VE）数据有限（3）。尚不知道COVID-19疫苗对SNF居民的保护程度如何，这些居民通常在医学上较虚弱，年龄较大，并且比普通人群具有更多的潜在医疗状况（1）。此外，发现在65-85岁的成年人中，Pfizer-BioNTech疫苗的免疫原性比年轻的成年人要低（4）。通过CDC长期护理计划药房合作伙伴关系，康涅狄格州的SNF居民和工作人员于2020年12月18日开始接受Pfizer-BioNTech COVID-19疫苗（5）。在几家现场药房诊所进行了疫苗接种。2021年1月下旬，康涅狄格州公共卫生部（CT DPH）确定了两个SNF，它们在每个机构的第一家疫苗接种诊所之后，在居民和工作人员中爆发了COVID-19疫情。CT DPH与CDC合作，在这些设施中进行了电子海图审查，以获取有关居民的疫苗接种状况和SARS-CoV-2（引起COVID-19的病毒）感染的信息。部分疫苗接种，定义为从第一次给药后> 14天到第二次给药后7天之间的时间段，这些SNF中的居民对SARS-CoV-2感染（不论症状如何）的估计有效性为63％（95％置信区间[CI] = 33％-79％）。这类似于在非聚集场所中不同年龄段的成年人中对成人使用单剂Pfizer-BioNTech COVID-19疫苗的估计有效性（6），并建议为了优化该人群中的疫苗效果，完整2的高覆盖率应建议SNF居民和工作人员使用剂量系列。